1
|
Balboni N, Babini G, Poeta E, Protti M, Mercolini L, Magnifico MC, Barile SN, Massenzio F, Pignataro A, Giorgi FM, Lasorsa FM, Monti B. Transcriptional and metabolic effects of aspartate-glutamate carrier isoform 1 (AGC1) downregulation in mouse oligodendrocyte precursor cells (OPCs). Cell Mol Biol Lett 2024; 29:44. [PMID: 38553684 PMCID: PMC10979587 DOI: 10.1186/s11658-024-00563-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2023] [Accepted: 03/20/2024] [Indexed: 04/02/2024] Open
Abstract
Aspartate-glutamate carrier isoform 1 (AGC1) is a carrier responsible for the export of mitochondrial aspartate in exchange for cytosolic glutamate and is part of the malate-aspartate shuttle, essential for the balance of reducing equivalents in the cells. In the brain, mutations in SLC25A12 gene, encoding for AGC1, cause an ultra-rare genetic disease, reported as a neurodevelopmental encephalopathy, whose symptoms include global hypomyelination, arrested psychomotor development, hypotonia and seizures. Among the biological components most affected by AGC1 deficiency are oligodendrocytes, glial cells responsible for myelination processes, and their precursors [oligodendrocyte progenitor cells (OPCs)]. The AGC1 silencing in an in vitro model of OPCs was documented to cause defects of proliferation and differentiation, mediated by alterations of histone acetylation/deacetylation. Disrupting AGC1 activity could possibly reduce the availability of acetyl groups, leading to perturbation of many biological pathways, such as histone modifications and fatty acids formation for myelin production. Here, we explore the transcriptome of mouse OPCs partially silenced for AGC1, reporting results of canonical analyses (differential expression) and pathway enrichment analyses, which highlight a disruption in fatty acids synthesis from both a regulatory and enzymatic stand. We further investigate the cellular effects of AGC1 deficiency through the identification of most affected transcriptional networks and altered alternative splicing. Transcriptional data were integrated with differential metabolite abundance analysis, showing downregulation of several amino acids, including glutamine and aspartate. Taken together, our results provide a molecular foundation for the effects of AGC1 deficiency in OPCs, highlighting the molecular mechanisms affected and providing a list of actionable targets to mitigate the effects of this pathology.
Collapse
Affiliation(s)
- Nicola Balboni
- Department of Pharmacy and Biotechnology, University of Bologna, Bologna, Italy
| | - Giorgia Babini
- Department of Pharmacy and Biotechnology, University of Bologna, Bologna, Italy
| | - Eleonora Poeta
- Department of Pharmacy and Biotechnology, University of Bologna, Bologna, Italy
| | - Michele Protti
- Department of Pharmacy and Biotechnology, University of Bologna, Bologna, Italy
| | - Laura Mercolini
- Department of Pharmacy and Biotechnology, University of Bologna, Bologna, Italy
| | - Maria Chiara Magnifico
- Department of Biosciences, Biotechnologies and Environment, University of Bari, Bari, Italy
| | - Simona Nicole Barile
- Department of Biosciences, Biotechnologies and Environment, University of Bari, Bari, Italy
| | - Francesca Massenzio
- Department of Pharmacy and Biotechnology, University of Bologna, Bologna, Italy
| | - Antonella Pignataro
- Department of Biosciences, Biotechnologies and Environment, University of Bari, Bari, Italy
| | - Federico M Giorgi
- Department of Pharmacy and Biotechnology, University of Bologna, Bologna, Italy.
| | | | - Barbara Monti
- Department of Pharmacy and Biotechnology, University of Bologna, Bologna, Italy.
| |
Collapse
|
2
|
De Leonardis F, Ahmed A, Vozza A, Capobianco L, Riley CL, Barile SN, Di Molfetta D, Tiziani S, DiGiovanni J, Palmieri L, Dolce V, Fiermonte G. Human mitochondrial uncoupling protein 3 functions as a metabolite transporter. FEBS Lett 2024; 598:338-346. [PMID: 38058167 PMCID: PMC10922436 DOI: 10.1002/1873-3468.14784] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2023] [Revised: 11/22/2023] [Accepted: 11/24/2023] [Indexed: 12/08/2023]
Abstract
Since its discovery, a major debate about mitochondrial uncoupling protein 3 (UCP3) has been whether its metabolic actions result primarily from mitochondrial inner membrane proton transport, a process that decreases respiratory efficiency and ATP synthesis. However, UCP3 expression and activity are induced by conditions that would seem at odds with inefficient 'uncoupled' respiration, including fasting and exercise. Here, we demonstrate that the bacterially expressed human UCP3, reconstituted into liposomes, catalyses a strict exchange of aspartate, malate, sulphate and phosphate. The R282Q mutation abolishes the transport activity of the protein. Although the substrate specificity and inhibitor sensitivity of UCP3 display similarity with that of its close homolog UCP2, the two proteins significantly differ in their transport mode and kinetic constants.
Collapse
Affiliation(s)
- Francesco De Leonardis
- Department of Bioscience, Biotechnology and Environment, University of Bari, 70125 Bari, Italy
| | - Amer Ahmed
- Department of Bioscience, Biotechnology and Environment, University of Bari, 70125 Bari, Italy
| | - Angelo Vozza
- Department of Bioscience, Biotechnology and Environment, University of Bari, 70125 Bari, Italy
| | - Loredana Capobianco
- Department of Biological and Environmental Sciences and Technologies, University of Salento, 73100 Lecce, Italy
| | - Christopher L. Riley
- Department of Nutritional Sciences, The University of Texas at Austin, Austin, TX 78712, USA
| | - Simona Nicole Barile
- Department of Bioscience, Biotechnology and Environment, University of Bari, 70125 Bari, Italy
| | - Daria Di Molfetta
- Department of Bioscience, Biotechnology and Environment, University of Bari, 70125 Bari, Italy
| | - Stefano Tiziani
- Department of Nutritional Sciences, The University of Texas at Austin, Austin, TX 78712, USA
| | - John DiGiovanni
- Division of Pharmacology and Toxicology, College of Pharmacy, The University of Texas at Austin, Austin, TX. USA
| | - Luigi Palmieri
- Department of Bioscience, Biotechnology and Environment, University of Bari, 70125 Bari, Italy
| | - Vincenza Dolce
- Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Rende, Italy
| | - Giuseppe Fiermonte
- Department of Bioscience, Biotechnology and Environment, University of Bari, 70125 Bari, Italy
| |
Collapse
|
3
|
Protti M, Cirrincione M, Palano S, Poeta E, Babini G, Magnifico MC, Barile SN, Balboni N, Massenzio F, Mahdavijalal M, Giorgi FM, Mandrioli R, Lasorsa FM, Monti B, Mercolini L. Targeted quantitative metabolic profiling of brain-derived cell cultures by semi-automated MEPS and LC-MS/MS. J Pharm Biomed Anal 2023; 236:115757. [PMID: 37801818 DOI: 10.1016/j.jpba.2023.115757] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2023] [Revised: 09/11/2023] [Accepted: 09/26/2023] [Indexed: 10/08/2023]
Abstract
The accurate characterisation of metabolic profiles is an important prerequisite to determine the rate and the efficiency of the metabolic pathways taking place in the cells. Changes in the balance of metabolites involved in vital processes such as glycolysis, tricarboxylic acid (TCA) cycle, oxidative phosphorylation (OXPHOS), as well as in the biochemical pathways related to amino acids, lipids, nucleotides, and their precursors reflect the physiological condition of the cells and may contribute to the development of various human diseases. The feasible and reliable measurement of a wide array of metabolites and biomarkers possesses great potential to elucidate physiological and pathological mechanisms, aid preclinical drug development and highlight potential therapeutic targets. An effective, straightforward, sensitive, and selective liquid chromatography-tandem mass spectrometry (LC-MS/MS) approach was developed for the simultaneous quali-quantitative analysis of 41 compounds in both cell pellet and cell growth medium obtained from brain-derived cell cultures. Sample pretreatment miniaturisation was achieved thanks to the development and optimisation of an original extraction/purification approach based on digitally programmed microextraction by packed sorbent (eVol®-MEPS). MEPS allows satisfactory and reproducible clean-up and preconcentration of both low-volume homogenate cell pellet lysate and cell growth medium with advantages including, but not limited to, minimal sample handling and method sustainability in terms of sample, solvents, and energy consumption. The MEPS-LC-MS/MS method showed good sensitivity, selectivity, linearity, and precision. As a proof of concept, the developed method was successfully applied to the analysis of both cell pellet and cell growth medium obtained from a line of mouse immortalised oligodendrocyte precursor cells (OPCs; Oli-neu cell line), leading to the unambiguous determination of all the considered target analytes. This method is thus expected to be suitable for targeted, quantitative metabolic profiling in most brain cell models, thus allowing accurate investigations on the biochemical pathways that can be altered in central nervous system (CNS) neuropathologies, including e.g., mitochondrial respiration and glycolysis, or use of specific nutrients for growth and proliferation, or lipid, amino acid and nucleotide metabolism.
Collapse
Affiliation(s)
- Michele Protti
- Research group of Pharmaco-Toxicological Analysis (PTA Lab), Department of Pharmacy and Biotechnology (FaBiT), Alma Mater Studiorum, University of Bologna, Via Belmeloro 6, 40126 Bologna, Italy
| | - Marco Cirrincione
- Research group of Pharmaco-Toxicological Analysis (PTA Lab), Department of Pharmacy and Biotechnology (FaBiT), Alma Mater Studiorum, University of Bologna, Via Belmeloro 6, 40126 Bologna, Italy
| | - Sarah Palano
- Research group of Pharmaco-Toxicological Analysis (PTA Lab), Department of Pharmacy and Biotechnology (FaBiT), Alma Mater Studiorum, University of Bologna, Via Belmeloro 6, 40126 Bologna, Italy
| | - Eleonora Poeta
- Cellular Neurobiology Lab, Department of Pharmacy and Biotechnology (FaBiT), Alma Mater Studiorum, University of Bologna, Via Selmi 3, 40126 Bologna, Italy
| | - Giorgia Babini
- Cellular Neurobiology Lab, Department of Pharmacy and Biotechnology (FaBiT), Alma Mater Studiorum, University of Bologna, Via Selmi 3, 40126 Bologna, Italy
| | - Maria Chiara Magnifico
- Department of Biosciences, Biotechnologies and Environment, University of Bari Aldo Moro, Via E. Orabona 4, 70125 Bari, Italy
| | - Simona Nicole Barile
- Department of Biosciences, Biotechnologies and Environment, University of Bari Aldo Moro, Via E. Orabona 4, 70125 Bari, Italy
| | - Nicola Balboni
- Cellular Neurobiology Lab, Department of Pharmacy and Biotechnology (FaBiT), Alma Mater Studiorum, University of Bologna, Via Selmi 3, 40126 Bologna, Italy
| | - Francesca Massenzio
- Cellular Neurobiology Lab, Department of Pharmacy and Biotechnology (FaBiT), Alma Mater Studiorum, University of Bologna, Via Selmi 3, 40126 Bologna, Italy
| | - Mohammadreza Mahdavijalal
- Research group of Pharmaco-Toxicological Analysis (PTA Lab), Department of Pharmacy and Biotechnology (FaBiT), Alma Mater Studiorum, University of Bologna, Via Belmeloro 6, 40126 Bologna, Italy
| | - Federico M Giorgi
- Computational Genomics Lab, Department of Pharmacy and Biotechnology (FaBiT), Alma Mater Studiorum - University of Bologna, Via Selmi 3, 40126 Bologna, Italy
| | - Roberto Mandrioli
- Department for Life Quality Studies, Alma Mater Studiorum - University of Bologna, Corso d'Augusto 237, 47921 Rimini, Italy
| | - Francesco M Lasorsa
- Department of Biosciences, Biotechnologies and Environment, University of Bari Aldo Moro, Via E. Orabona 4, 70125 Bari, Italy; National Research Council (CNR) Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies (IBIOM), Via Giovanni Amendola 122, 70126 Bari, Italy
| | - Barbara Monti
- Cellular Neurobiology Lab, Department of Pharmacy and Biotechnology (FaBiT), Alma Mater Studiorum, University of Bologna, Via Selmi 3, 40126 Bologna, Italy
| | - Laura Mercolini
- Research group of Pharmaco-Toxicological Analysis (PTA Lab), Department of Pharmacy and Biotechnology (FaBiT), Alma Mater Studiorum, University of Bologna, Via Belmeloro 6, 40126 Bologna, Italy.
| |
Collapse
|
4
|
Messina E, de Souza CP, Cappella C, Barile SN, Scarcia P, Pisano I, Palmieri L, Nicaud JM, Agrimi G. Genetic inactivation of the Carnitine/Acetyl-Carnitine mitochondrial carrier of Yarrowia lipolytica leads to enhanced odd-chain fatty acid production. Microb Cell Fact 2023; 22:128. [PMID: 37443049 DOI: 10.1186/s12934-023-02137-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2023] [Accepted: 06/26/2023] [Indexed: 07/15/2023] Open
Abstract
BACKGROUND Mitochondrial carriers (MCs) can deeply affect the intracellular flux distribution of metabolic pathways. The manipulation of their expression level, to redirect the flux toward the production of a molecule of interest, is an attractive target for the metabolic engineering of eukaryotic microorganisms. The non-conventional yeast Yarrowia lipolytica is able to use a wide range of substrates. As oleaginous yeast, it directs most of the acetyl-CoA therefrom generated towards the synthesis of lipids, which occurs in the cytoplasm. Among them, the odd-chain fatty acids (OCFAs) are promising microbial-based compounds with several applications in the medical, cosmetic, chemical and agricultural industries. RESULTS In this study, we have identified the MC involved in the Carnitine/Acetyl-Carnitine shuttle in Y. lipolytica, YlCrc1. The Y. lipolytica Ylcrc1 knock-out strain failed to grow on ethanol, acetate and oleic acid, demonstrating the fundamental role of this MC in the transport of acetyl-CoA from peroxisomes and cytoplasm into mitochondria. A metabolic engineering strategy involving the deletion of YlCRC1, and the recombinant expression of propionyl-CoA transferase from Ralstonia eutropha (RePCT), improved propionate utilization and its conversion into OCFAs. These genetic modifications and a lipogenic medium supplemented with glucose and propionate as the sole carbon sources, led to enhanced accumulation of OCFAs in Y. lipolytica. CONCLUSIONS The Carnitine/Acetyl-Carnitine shuttle of Y. lipolytica involving YlCrc1, is the sole pathway for transporting peroxisomal or cytosolic acetyl-CoA to mitochondria. Manipulation of this carrier can be a promising target for metabolic engineering approaches involving cytosolic acetyl-CoA, as demonstrated by the effect of YlCRC1 deletion on OCFAs synthesis.
Collapse
Affiliation(s)
- Eugenia Messina
- Department of Biosciences, Biotechnology and Environment, University of Bari "Aldo Moro", Campus Universitario, via Orabona 4, Bari, 70125, Italy
- Université Paris-Saclay, INRAE, Micalis Institute, Jouy-en-Josas, 78350, AgroParisTech, France
| | - Camilla Pires de Souza
- Université Paris-Saclay, INRAE, Micalis Institute, Jouy-en-Josas, 78350, AgroParisTech, France
| | - Claudia Cappella
- Department of Biosciences, Biotechnology and Environment, University of Bari "Aldo Moro", Campus Universitario, via Orabona 4, Bari, 70125, Italy
| | - Simona Nicole Barile
- Department of Biosciences, Biotechnology and Environment, University of Bari "Aldo Moro", Campus Universitario, via Orabona 4, Bari, 70125, Italy
| | - Pasquale Scarcia
- Department of Biosciences, Biotechnology and Environment, University of Bari "Aldo Moro", Campus Universitario, via Orabona 4, Bari, 70125, Italy
| | - Isabella Pisano
- Department of Biosciences, Biotechnology and Environment, University of Bari "Aldo Moro", Campus Universitario, via Orabona 4, Bari, 70125, Italy
| | - Luigi Palmieri
- Department of Biosciences, Biotechnology and Environment, University of Bari "Aldo Moro", Campus Universitario, via Orabona 4, Bari, 70125, Italy
- Bioenergetics and Molecular Biotechnologies (IBIOM), CNR Institute of Biomembranes, Campus Universitario, via Orabona 4, Bari, 70125, Italy
| | - Jean-Marc Nicaud
- Université Paris-Saclay, INRAE, Micalis Institute, Jouy-en-Josas, 78350, AgroParisTech, France.
| | - Gennaro Agrimi
- Department of Biosciences, Biotechnology and Environment, University of Bari "Aldo Moro", Campus Universitario, via Orabona 4, Bari, 70125, Italy.
| |
Collapse
|
5
|
De Leonardis F, Barile SN, Cianci C, Pisano I, Merla G, Pappalettera G, Casavola C, Pappalettere C. In Vitro Effects of Low-energy Ultrasound Treatment on Healthy CD3/CD8+ Lymphocytes, Red blood cells, Acute Myeloid leukemia cells, and Jurkat cell line. J Cancer 2023; 14:1088-1106. [PMID: 37215443 PMCID: PMC10197932 DOI: 10.7150/jca.83050] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2023] [Accepted: 03/09/2023] [Indexed: 05/24/2023] Open
Abstract
The study of the biological effects of low-energy ultrasound and its applications is a rapidly expanding research area. Low-energy ultrasound could be used as anti-tumoral therapy with or without the pharmacological combination even if the second situation has been scarcely investigated up to now. Very little information is available about the ultrasound effects on healthy red blood cells, CD3, and mainly CD8 subset lymphocytes which is the main subset cell having cytotoxic function towards cancer cells. In this study, we investigated in vitro the bioeffects of low energy ultrasound on red blood cells and PBMCs isolated from healthy donors as well as on two myeloid leukemia cell lines (OCI- AML-3 MOLM-13) and lymphoblastic Jurkat cell line. Using low-energy ultrasound (US), a study was conducted to determine how it affects CD3/CD8 lymphocytes and leukemia cells, as well as its potential role in treating blood cancers, by analyzing changes in mitochondrial membrane potential, phosphatidylserine asymmetry, morphological changes for myeloid AML cell lines, proliferation and cytotoxic activation of healthy lymphocytes, and apoptosis for RBCs after US exposure. Overall, we demonstrated that CD3/CD8 lymphocytes proliferation/activation and cytotoxic functions are fully preserved after ultrasound treatments, whereas leukemia cell lines undergo apoptosis and stop proliferating suggesting a potential method of treating blood cancer.
Collapse
Affiliation(s)
- Francesco De Leonardis
- Dept. Bioscience Biotechnology and Environment, University of Bari” A. Moro”, Bari, 70125, Italy
| | - Simona Nicole Barile
- Dept. Bioscience Biotechnology and Environment, University of Bari” A. Moro”, Bari, 70125, Italy
| | - Claudia Cianci
- Dept. of Mechanics, Mathematics, and Management, Polytechnic University of Bari, Bari, 70125, Italy
| | - Isabella Pisano
- Dept. Bioscience Biotechnology and Environment, University of Bari” A. Moro”, Bari, 70125, Italy
| | - Giuseppe Merla
- Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples, 8013, Italy
| | - Giovanni Pappalettera
- Dept. of Mechanics, Mathematics, and Management, Polytechnic University of Bari, Bari, 70125, Italy
| | - Caterina Casavola
- Dept. of Mechanics, Mathematics, and Management, Polytechnic University of Bari, Bari, 70125, Italy
| | - Carmine Pappalettere
- Dept. of Mechanics, Mathematics, and Management, Polytechnic University of Bari, Bari, 70125, Italy
| |
Collapse
|
6
|
Poeta E, Petralla S, Babini G, Renzi B, Celauro L, Magnifico MC, Barile SN, Masotti M, De Chirico F, Massenzio F, Viggiano L, Palmieri L, Virgili M, Lasorsa FM, Monti B. Histone Acetylation Defects in Brain Precursor Cells: A Potential Pathogenic Mechanism Causing Proliferation and Differentiation Dysfunctions in Mitochondrial Aspartate-Glutamate Carrier Isoform 1 Deficiency. Front Cell Neurosci 2022; 15:773709. [PMID: 35095421 PMCID: PMC8790092 DOI: 10.3389/fncel.2021.773709] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2021] [Accepted: 11/29/2021] [Indexed: 11/13/2022] Open
Abstract
Mitochondrial aspartate-glutamate carrier isoform 1 (AGC1) deficiency is an ultra-rare genetic disease characterized by global hypomyelination and brain atrophy, caused by mutations in the SLC25A12 gene leading to a reduction in AGC1 activity. In both neuronal precursor cells and oligodendrocytes precursor cells (NPCs and OPCs), the AGC1 determines reduced proliferation with an accelerated differentiation of OPCs, both associated with gene expression dysregulation. Epigenetic regulation of gene expression through histone acetylation plays a crucial role in the proliferation/differentiation of both NPCs and OPCs and is modulated by mitochondrial metabolism. In AGC1 deficiency models, both OPCs and NPCs show an altered expression of transcription factors involved in the proliferation/differentiation of brain precursor cells (BPCs) as well as a reduction in histone acetylation with a parallel alteration in the expression and activity of histone acetyltransferases (HATs) and histone deacetylases (HDACs). In this study, histone acetylation dysfunctions have been dissected in in vitro models of AGC1 deficiency OPCs (Oli-Neu cells) and NPCs (neurospheres), in physiological conditions and following pharmacological treatments. The inhibition of HATs by curcumin arrests the proliferation of OPCs leading to their differentiation, while the inhibition of HDACs by suberanilohydroxamic acid (SAHA) has only a limited effect on proliferation, but it significantly stimulates the differentiation of OPCs. In NPCs, both treatments determine an alteration in the commitment toward glial cells. These data contribute to clarifying the molecular and epigenetic mechanisms regulating the proliferation/differentiation of OPCs and NPCs. This will help to identify potential targets for new therapeutic approaches that are able to increase the OPCs pool and to sustain their differentiation toward oligodendrocytes and to myelination/remyelination processes in AGC1 deficiency, as well as in other white matter neuropathologies.
Collapse
Affiliation(s)
- Eleonora Poeta
- Department of Pharmacy and Biotechnology, University of Bologna, Bologna, Italy
| | - Sabrina Petralla
- Department of Pharmacy and Biotechnology, University of Bologna, Bologna, Italy
| | - Giorgia Babini
- Department of Pharmacy and Biotechnology, University of Bologna, Bologna, Italy
| | - Brunaldo Renzi
- Department of Pharmacy and Biotechnology, University of Bologna, Bologna, Italy
| | - Luigi Celauro
- Department of Pharmacy and Biotechnology, University of Bologna, Bologna, Italy
| | - Maria Chiara Magnifico
- Department of Biosciences, Biotechnologies and Biopharmaceutics, University of Bari Aldo Moro, Bari, Italy
| | - Simona Nicole Barile
- CNR Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies, Bari, Italy
| | - Martina Masotti
- Department of Pharmacy and Biotechnology, University of Bologna, Bologna, Italy
| | | | - Francesca Massenzio
- Department of Pharmacy and Biotechnology, University of Bologna, Bologna, Italy
| | - Luigi Viggiano
- Department of Biology, University of Bari Aldo Moro, Bari, Italy
| | - Luigi Palmieri
- Department of Biosciences, Biotechnologies and Biopharmaceutics, University of Bari Aldo Moro, Bari, Italy,CNR Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies, Bari, Italy
| | - Marco Virgili
- Department of Pharmacy and Biotechnology, University of Bologna, Bologna, Italy
| | - Francesco Massimo Lasorsa
- Department of Biosciences, Biotechnologies and Biopharmaceutics, University of Bari Aldo Moro, Bari, Italy,CNR Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies, Bari, Italy,*Correspondence: Francesco Massimo Lasorsa,
| | - Barbara Monti
- Department of Pharmacy and Biotechnology, University of Bologna, Bologna, Italy,Barbara Monti,
| |
Collapse
|
7
|
Petralla S, Peña-Altamira LE, Poeta E, Massenzio F, Virgili M, Barile SN, Sbano L, Profilo E, Corricelli M, Danese A, Giorgi C, Ostan R, Capri M, Pinton P, Palmieri F, Lasorsa FM, Monti B. Deficiency of Mitochondrial Aspartate-Glutamate Carrier 1 Leads to Oligodendrocyte Precursor Cell Proliferation Defects Both In Vitro and In Vivo. Int J Mol Sci 2019; 20:ijms20184486. [PMID: 31514314 PMCID: PMC6769484 DOI: 10.3390/ijms20184486] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2019] [Revised: 09/04/2019] [Accepted: 09/06/2019] [Indexed: 11/16/2022] Open
Abstract
Aspartate-Glutamate Carrier 1 (AGC1) deficiency is a rare neurological disease caused by mutations in the solute carrier family 25, member 12 (SLC25A12) gene, encoding for the mitochondrial aspartate-glutamate carrier isoform 1 (AGC1), a component of the malate-aspartate NADH shuttle (MAS), expressed in excitable tissues only. AGC1 deficiency patients are children showing severe hypotonia, arrested psychomotor development, seizures and global hypomyelination. While the effect of AGC1 deficiency in neurons and neuronal function has been deeply studied, little is known about oligodendrocytes and their precursors, the brain cells involved in myelination. Here we studied the effect of AGC1 down-regulation on oligodendrocyte precursor cells (OPCs), using both in vitro and in vivo mouse disease models. In the cell model, we showed that a reduced expression of AGC1 induces a deficit of OPC proliferation leading to their spontaneous and precocious differentiation into oligodendrocytes. Interestingly, this effect seems to be related to a dysregulation in the expression of trophic factors and receptors involved in OPC proliferation/differentiation, such as Platelet-Derived Growth Factor α (PDGFα) and Transforming Growth Factor βs (TGFβs). We also confirmed the OPC reduction in vivo in AGC1-deficent mice, as well as a proliferation deficit in neurospheres from the Subventricular Zone (SVZ) of these animals, thus indicating that AGC1 reduction could affect the proliferation of different brain precursor cells. These data clearly show that AGC1 impairment alters myelination not only by acting on N-acetyl-aspartate production in neurons but also on OPC proliferation and suggest new potential therapeutic targets for the treatment of AGC1 deficiency.
Collapse
Affiliation(s)
- Sabrina Petralla
- Department of Pharmacy and BioTechnology, University of Bologna, 40126 Bologna, Italy; (S.P.); (L.E.P.-A.); (E.P.); (F.M.); (M.V.)
| | - Luis Emiliano Peña-Altamira
- Department of Pharmacy and BioTechnology, University of Bologna, 40126 Bologna, Italy; (S.P.); (L.E.P.-A.); (E.P.); (F.M.); (M.V.)
| | - Eleonora Poeta
- Department of Pharmacy and BioTechnology, University of Bologna, 40126 Bologna, Italy; (S.P.); (L.E.P.-A.); (E.P.); (F.M.); (M.V.)
| | - Francesca Massenzio
- Department of Pharmacy and BioTechnology, University of Bologna, 40126 Bologna, Italy; (S.P.); (L.E.P.-A.); (E.P.); (F.M.); (M.V.)
| | - Marco Virgili
- Department of Pharmacy and BioTechnology, University of Bologna, 40126 Bologna, Italy; (S.P.); (L.E.P.-A.); (E.P.); (F.M.); (M.V.)
| | - Simona Nicole Barile
- Department of Biosciences, Biotechnologies and Biopharmaceutics, University of Bari, 70121 Bari, Italy (E.P.); (F.P.)
| | - Luigi Sbano
- Department of Morphology, Surgery and Experimental Medicine, Section of Pathology, Oncology and Experimental Biology, Laboratory for Technologies of Advanced Therapies (LTTA), University of Ferrara, 44121 Ferrara, Italy; (L.S.); (M.C.); (A.D.); (C.G.); (P.P.)
| | - Emanuela Profilo
- Department of Biosciences, Biotechnologies and Biopharmaceutics, University of Bari, 70121 Bari, Italy (E.P.); (F.P.)
| | - Mariangela Corricelli
- Department of Morphology, Surgery and Experimental Medicine, Section of Pathology, Oncology and Experimental Biology, Laboratory for Technologies of Advanced Therapies (LTTA), University of Ferrara, 44121 Ferrara, Italy; (L.S.); (M.C.); (A.D.); (C.G.); (P.P.)
| | - Alberto Danese
- Department of Morphology, Surgery and Experimental Medicine, Section of Pathology, Oncology and Experimental Biology, Laboratory for Technologies of Advanced Therapies (LTTA), University of Ferrara, 44121 Ferrara, Italy; (L.S.); (M.C.); (A.D.); (C.G.); (P.P.)
| | - Carlotta Giorgi
- Department of Morphology, Surgery and Experimental Medicine, Section of Pathology, Oncology and Experimental Biology, Laboratory for Technologies of Advanced Therapies (LTTA), University of Ferrara, 44121 Ferrara, Italy; (L.S.); (M.C.); (A.D.); (C.G.); (P.P.)
| | - Rita Ostan
- Department of Experimental, Diagnostic and Specialty Medicine (DIMES, Dipartimento di Medicina Specialistica Diagnostica e Sperimentale) and C.I.G. Interdepartmental Centre “L. Galvani”, University of Bologna, 40126 Bologna, Italy; (R.O.); (M.C.)
| | - Miriam Capri
- Department of Experimental, Diagnostic and Specialty Medicine (DIMES, Dipartimento di Medicina Specialistica Diagnostica e Sperimentale) and C.I.G. Interdepartmental Centre “L. Galvani”, University of Bologna, 40126 Bologna, Italy; (R.O.); (M.C.)
| | - Paolo Pinton
- Department of Morphology, Surgery and Experimental Medicine, Section of Pathology, Oncology and Experimental Biology, Laboratory for Technologies of Advanced Therapies (LTTA), University of Ferrara, 44121 Ferrara, Italy; (L.S.); (M.C.); (A.D.); (C.G.); (P.P.)
- Maria Cecilia Hospital, GVM Care & Research, Cotignola, 48010 Ravenna, Italy
| | - Ferdinando Palmieri
- Department of Biosciences, Biotechnologies and Biopharmaceutics, University of Bari, 70121 Bari, Italy (E.P.); (F.P.)
- Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies IBIOM, CNR, 70126 Bari, Italy
| | - Francesco Massimo Lasorsa
- Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies IBIOM, CNR, 70126 Bari, Italy
- Correspondence: (F.M.L.); (B.M.); Tel.: +39-080-544-2772 (F.M.L.); +39-051-209-4134 (B.M.)
| | - Barbara Monti
- Department of Pharmacy and BioTechnology, University of Bologna, 40126 Bologna, Italy; (S.P.); (L.E.P.-A.); (E.P.); (F.M.); (M.V.)
- Correspondence: (F.M.L.); (B.M.); Tel.: +39-080-544-2772 (F.M.L.); +39-051-209-4134 (B.M.)
| |
Collapse
|